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Abstract.
Background: Continuous intra-duodenal infusion of levodopa-carbidopa intestinal gel (LCIG) is a well-established therapy
for patients with advanced Parkinson’s disease (PD) suffering from motor complications despite optimized treatment with
oral dopaminomimetics. However, time to discontinuation of treatment with LCIG varies considerably between patients,
ranging from a few months to more than ten years. To improve the selection of candidates for LCIG, knowledge of prognostic
factors is of paramount importance.
Objective: To explore baseline predictors of time to discontinuation of LCIG.
Methods: In this two-center retrospective cohort study, we reviewed the medical files of 98 PD patients treated with LCIG
between April 2006 and December 2015 (53% male; mean age: 66.2 years; mean disease duration: 12.3 years). Baseline
patient characteristics were used as covariates in Cox regression models.
Results: During follow-up (mean observation time: 2.6 years; range: 0.1–9.3) eighteen patients discontinued treatment
(18.4%), while seven patients died (7.1%). Median duration of treatment with LCIG, estimated with Kaplan-Meier analysis,
was 7.8 years (95% CI: 6.7–9.0). Disease duration (in years) at baseline was a statistically significant predictor of time to
discontinuation of LCIG (HR: 0.85; 95% CI: 0.75–0.96, p = 0.006). All other characteristics studied, e.g. age >70 years, did
not show statistically significant associations with the total duration of treatment with LCIG.
Conclusion: Our findings show a low overall rate of discontinuation of LCIG infusion, with a median duration of treatment
of 7.8 years. Shorter disease duration at baseline appeared to be a predictor of earlier discontinuation of LCIG.
Keywords: Parkinson disease, carbidopa, levodopa drug combination, duodopa, treatment adherence, drug-related side effects
and adverse reactions, survival analysis, Kaplan-Meier estimate, regression analysis, observational study, retrospective study
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INTRODUCTION
Within ten years of treatment with oral
dopaminomimetics, many patients with Parkinson’s
disease (PD) develop disabling motor complications
consisting of at random on-off fluctuations as well as
troublesome dyskinesias [1–3], These phenomena
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can be partly explained by variations in the levodopa
plasma concentration, caused by, e.g., variable
gastric emptying, among several other reasons [4].
Since 2004, continuous intra-duodenal infusion of
levodopa-carbidopa intestinal gel (LCIG) has been
available to alleviate motor complications not ade-
quately controlled by oral therapy [5, 6]. LCIG
infusion provides stable levodopa concentrations in
plasma, thereby reducing off time and increasing on
time without troublesome dyskinesias [7, 8]. LCIG
does also appear to reduce non-motor symptoms [9].
LCIG infusion is well-tolerated in the long term, as
evidenced by an average overall duration of treatment
of 7.6 years [10].
However, time to discontinuation differs consider-
ably among patients, ranging from a few months to
more than ten years [10, 11]. This variation suggests
individual differences in the overall effectiveness of
LCIG, since the total duration of treatment reflects the
therapeutic benefits in relation to undesirable effects
[12]. Indeed, reasons for discontinuation of LCIG
are most commonly device-related complications,
lack of efficacy, patient dissatisfaction, drug-related
adverse events and death (unrelated to LCIG) [10,
13–16]. Identifying patient characteristics related to
the heterogeneity of overall effectiveness of LCIG
under real-word conditions is crucial to improving
patient selection criteria [17, 18].
Several small and medium-sized cohort studies
identified baseline characteristics associated with
early discontinuation of LCIG infusion. A Swedish
cohort study with 135 patients reported that longer
disease duration at baseline was a risk factor for
discontinuation [10]. In addition, smaller follow-up
studies (20 to 59 patients) observed associations with
high age at implant (>70 years), low severity of
pre-pump dyskinesias, and female sex [15, 19, 20].
However, none of the identified predictors have been
confirmed by other studies.
Therefore, we studied a cohort of cohort of 98 PD
patients to establish whether baseline characteristics
are predictors of time to discontinuation of LCIG.
MATERIALS AND METHODS
Design and setting
This was a retrospective cohort study conducted
in two departments of neurology in the Netherlands,
both specialized in movement disorders and each
serving a PD population of 500–700 patients. Both
centers offer all three advanced PD therapies, namely
continuous apomorphine infusion (CAI), LCIG and
deep brain stimulation (DBS). In both hospitals, the
initiation and management of LCIG is carried out by
a dedicated team consisting of a movement disorder
specialist, a specialized PD nurse, a gastroenterol-
ogist and an interventional radiologist. The local
standard operating procedures are updated annually
in accordance with the most recent scientific evi-
dence.
This study was reported as per the Strengthening
the Reporting of Observational Studies in Epidemi-
ology (STROBE) guideline [21].
Ethical approval
The study protocol was approved by the ethi-
cal review committee of the Zuyderland Medical
Center, whereas an exemption was granted by the
ethical review board of the University Medical Cen-
ter Groningen. All medical charts were reviewed in
accordance with the prevailing regulations on data
protection and privacy.
Patients and medical charts
PD patients who started treatment with LCIG
infusion between April 1st, 2006 and December
31st, 2015 (study cut-off date) were included. The
included patients fulfilled the UK Brain Bank cri-
teria for the diagnosis of idiopathic PD [22]. In
addition, all patients had advanced PD with motor
fluctuations, often with dyskinesias, despite optimal
oral/transdermal drug treatment. A minority of the
studied patients had already been treated with DBS,
CAI or both.
The decision to start treatment with LCIG was
made after careful consideration of other treatment
options (continuing oral treatment, DBS or CAI).
The patients and their caregivers were involved in
this decision-making process after they had been
informed about the options. LCIG infusion (levodopa
(20 mg/mL) and carbidopa (5 mg/mL) in methylcel-
lulose)) was initiated in accordance with the standard
operating procedures of both hospitals. In one of the
centers, a nasojejunal test phase was performed in all
patients, whereas in the other hospital this was left
to the discretion of the treating neurologist. Patients
who did not continue LCIG infusion after an initial
nasojejunal test phase were excluded from the cohort,
as well as patients whose medical files could not be
retrieved.
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The electronical medical charts comprised all
reports of hospitalizations, outpatient care visits, drug
changes, radiological examinations and invasive pro-
cedures, as well as medical correspondence between
hospitals.
Endpoints and predictor variables
The primary endpoint of this study was time to
discontinuation of LCIG infusion (excluding death).
As death was a so-called competing risk (i.e., a
patient who dies during treatment with LCIG can no
longer discontinue LCIG infusion), we chose time to
all-cause discontinuation of LCIG infusion (includ-
ing death) as a sensitivity analysis for the primary
endpoint. Secondary endpoints were number of dis-
continuations, reasons for treatment discontinuation,
and number of hospitalizations due to LCIG-related
complications. A hospitalization was defined as an
admission to the hospital for clinical observation or
treatment for the duration of at least one day.
The following baseline variables were selected
as potential predictors of time to discontinuation of
LCIG infusion: gender, age at diagnosis PD, age at
start of LCIG infusion, disease duration at start of
LCIG, levodopa equivalent daily dose (LEDD), dis-
ease severity (Hoehn and Yahr stage), marital state,
living situation (home or institution), subject to naso-
jejunal test phase (yes or no), presence of severe
cognitive impairment, type of enteral access system
(PEG-J or T-port), prior advanced therapies (DBS
and/or CAI), and having ≥1 somatic comorbidity.
The predictor variable age at the start of LCIG was
dichotomized, using a cut-off of 70 years, in order
to compare our data with the findings from previous
studies [15, 23]. Potential predictor variables with
large numbers of missing values (>30%) were not
analyzed.
Data acquisition
Between November 2015 and January 2016, the
medical files of all included patients were systemati-
cally reviewed by two authors (H.M. and J.G.).
Time to discontinuation (in months) was calcu-
lated as the time interval between initiation of LCIG
and discontinuation of treatment. If patients died or
were lost to follow-up (e.g., moved elsewhere) or
were still on LCIG infusion at study cut-off, their
durations of treatment were censored at the last avail-
able follow-up. For the sensitivity analysis of time to
all-cause discontinuation, death was considered as a
reason for discontinuation of treatment. In patients
who restarted LCIG infusion after having discon-
tinued LCIG, only the first treatment period was
evaluated.
Disease duration was calculated as the number of
months between the date of diagnosis and the start
of LCIG infusion. If medical records only stated the
year of PD diagnosis, the corresponding month was
arbitrarily set on June.
Levodopa equivalent daily dose (LEDD) before
start of LCIG and after initiation of LCIG was cal-
culated using the formula described elsewhere [24].
In case the daily dosing times of LCIG could not be
retrieved from the medical file, a 16-hour-treatment
per day was assumed. Presence of severe cognitive
impairment was deduced from the medical chart in
case the wording ‘PD dementia’ had been included
in the file by the treating neurologist, or in case the
patient had ‘severe cognitive impairment’ and did use
a cholinesterase inhibitor.
Reasons for treatment discontinuation were
deduced from clinical reports and categorized as
follows: treatment effect being less than expected;
switch to DBS; switch to CAI; device-related side
effects (e.g., events related to the intestinal tube,
pump complications, or infusion-related events); or
drug-related side effects (e.g., dyskinesia, neuropsy-
chiatric side effects, severe neuropathy). Death was
categorized as being either related or unrelated to
LCIG infusion.
Statistical analyses
Patient demographics at baseline were summarized
using descriptive statistics. Quantitative data were
expressed as mean and standard deviation, whereas
categorical variables were presented as counts and
proportions (%). No attempts were made to impute
missing values.
We used Kaplan-Meier curves to estimate the time
to discontinuation of treatment and the overall median
duration of treatment. This analysis accounted for
censored observations. The number of LCIG-related
hospitalizations was reported as an incidence rate
(total number of hospitalizations divided by the
cumulative observation time of the whole cohort), as
to account for variations in observation time among
the included patients.
To identify predictors of the time to discontinuation
of treatment with LCIG, we used Cox proportional
hazard models. The proportional hazards assumption
was verified for all potential predictors by means of
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Schoenfield residual tests (performed in R version
3.3.1 with the package ‘Survival’) [25, 26]. Outcomes
of the Cox regression analyses were reported as haz-
ard ratios (HR) with corresponding 95% confidence
intervals (95% CI).
Subsequently, a multivariable Cox regression anal-
ysis was performed including all potential univariable
correlates (p < 0.157; Akaike information criterion)
using a backward stepwise selection with a p value
>0.05 for removal of variables [27]. Because of the
pure predictive nature of this study, there was no
need to consider confounding effects (i.e., no causal
mechanisms were studied) [28].
Time-to-event analyses and the statistical analyses
for the baseline table were carried out using IBM
SPSS Statistics version 25 for Windows. We used
STATA version 16 (StataCorp LLC) for Windows to
calculate incidence rates. The significance threshold
was set at p < 0.05.
RESULTS
In the two hospitals, a total number of 106 eligi-
ble PD patients were identified. Of this group, five
patients did not continue treatment with LCIG after
the initial test phase, whereas three patients were
excluded because their medical records could not be
retrieved. Therefore, the final study cohort consisted
of 98 patients (53.1% male) on long-term LCIG infu-
sion (Fig. 1).
Fig. 1. Patient flow chart. LCIG, levodopa-carbidopa intestinal gel.
Baseline characteristics of the included patients are
reported in Table 1. At start of LCIG therapy, the mean
age was 66.2 ± 8.2 years and the mean duration of
PD was 12.3 ± 5.4 years. A nasojejunal test phase
was performed in 44 patients (44.9%). Most patients
(85.7%) received LCIG infusion via a PEG-J tube.
The others received a T-port [29].
Before starting with LCIG infusion, 29 patients
(29.6%) had been treated with other advanced thera-
pies, namely CAI (n = 24; on average 1.9 ± 1.6 years
before LCIG) or both CAI and DBS (n = 5; on average
Table 1
Demographic and clinical characteristics of study population at
start of LCIG infusion
Characteristic N = 98 Missing
values
Male gender 52 (53.1%)
Age (years) 66.2 ± 8.2
Age ≥ 70 years 34 (34.7%)
Duration of PD (years) 12.3 ± 5.4
Age at diagnosis PD (years) 53.8 ± 8.9














LEDD oral medication 1437 ± 493 2
LEDD using LCIG 1649 ± 611 3
Previous advanced therapy
CAI 24 (25.0%)
Years before LCIG 1.9 ± 1.6
CAI and DBS§ 5 (5.2%)
Years before LCIG 4.2 ± 2.2
Severe cognitive impairment 12 (12.2%) 40
Somatic comorbidity
≥1 comorbidity 45 (45.9%)
Arthrosis 16 (16.3%)
COPD 1 (1.0%)
Coronary artery disease 9 (9.2%)
Diabetes mellitus 11 (11.2%)




Variables are expressed as number (percentage) or mean ± SD.
CAI, continuous apomorphine infusion; DBS, deep brain stimu-
lation; LCIG, levodopa-carbidopa intestinal gel; PD, Parkinson’s
disease; PEG-J, percutaneous endoscopic gastrostomy with a jeju-
nal tube; SD, standard deviation. *The proportions are calculated
from the number of available observations (n = 50). §4 out of 5
patients had already been using CAI before starting with DBS.
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Fig. 2. Kaplan-Meier curve showing time to discontinuation of levodopa-carbidopa intestinal gel (LCIG) infusion. The vertical tick marks
denote censored observations. The horizontal dashed lines indicate the median time to discontinuation of treatment. A) Curve for the
primary analysis of time to discontinuation (patients discontinued: n = 18); censored observations include deceased patients. B) Curve for
the sensitivity analysis in which death is considered a discontinuation of treatment (patients discontinued or died: n = 25).
4.2 ± 2.2 years before LCIG). No patients continued
CAI once they started with LCIG, though four of
the five patients treated with DBS did combine this
therapy with LCIG infusion.
Time to discontinuation
The mean observation time of this study was
2.6 ± 2.4 years, ranging from one month up to 9.3
years. In seventeen patients (17.3%) the observation
time was more than 5.0 years.
During the overall observation period, 18 patients
(18.4%) discontinued LCIG infusion, while seven
patients died (7.1%). The median time to discontin-
uation of treatment with LCIG, as estimated with
Kaplan-Meier analysis, was 7.8 years (95% CI:
6.7–9.0; Fig. 2A). This result was similar in the
sensitivity analysis in which death was considered
a discontinuation of treatment (median time to all-
cause discontinuation: 7.8 years; 95% CI: 6.8–8.9;
Fig. 2B). The patient who had the longest observa-
tion time (9.3 years) was still using LCIG infusion
at the last follow-up. The rate of discontinuation
appeared to be higher during the first two years of
treatment, judging from the steepness of the curve
(Fig. 2A). The same holds for the sensitivity analysis
(Fig. 2B).
Among the 18 patients who discontinued treat-
ment, four patients restarted LCIG infusion after a
median duration of 0.8 years (range: 0.4–3.3), typi-
cally because their response fluctuations could not be
managed adequately by either DBS or oral dopamin-
ergic therapy.
Predictors of time to discontinuation
Outcomes of both the univariable and multivari-
able Cox regression models are shown in Table 2.
Univariable analysis showed that duration of PD (in
years) at start of LCIG was a significant predictor of
treatment discontinuation (Hazard Ratio (HR): 0.85;
95% CI: 0.75–0.96; p = 0.006). An HR < 1 indicates a
lower risk of discontinuation for every 1-year increase
in disease duration at start of treatment. Higher age
(in years) at baseline was also associated with a
lower risk of discontinuation, although not statisti-
cally significant (HR: 0.95; p = 0.09). This variable
was selected for the multivariable analysis based on
the Akaike information criterion (p < 0.157). No other
baseline characteristics studied were associated with
time to discontinuation.
Disease severity (Hoehn & Yahr score) and
presence of severe cognitive impairment were not
analyzed as potential predictors because of the
940 H.R. Moes et al. / Predictors of Time to Discontinuation of LCIG
Table 2
Associations between baseline characteristics and time to discontinuation of LCIG infusion
Variable at start of LCIG infusion Univariable regression Multivariable regression
HR 95% CI p-value HR 95% CI p-value
Gender (male vs female) 0.88 0.35–2.24 0.79
Age
(years) 0.95 0.89–1.01 0.09 0.95 0.89–1.02 0.14
(≥70 years vs <70 years) 0.74 0.23–2.34 0.61
Duration of PD (years) 0.85 0.75–0.96 0.006* 0.85 0.76–0.96 0.009*
Age at diagnosis PD (years) 1.00 0.95–1.06 0.89
Partner/relationship (yes vs no)§ 1.21 0.34–4.27 0.77
Living situation (home vs institution)¶ 0.71 0.26–3.19 0.66
Enteral access (PEG-J vs T-port) 1.29 0.29–5.73 0.74
LEDD oral medication (mg/day) 1.00 0.99–1.00 0.62
LEDD at remission from hospital (mg/day) 1.00 0.99–1.00 0.60
Prior advanced therapy (yes vs no) 1.39 0.53–3.64 0.51
Somatic comorbidity (≥1 vs 0) 2.02 0.79–5.19 0.18
CI, confidence interval; HR, hazard ratio; LCIG, levodopa-carbidopa intestinal gel; PD, Parkinson’s disease; PEG-J, percutaneous endoscopic
gastrostomy with a jejunal tube. * Statistically significant (p < 0.05). § N = 93; in total 17 discontinuations. ¶ N = 94; in total 18 discontinuations.
high number of missing values (49% and 41%,
respectively).
The multivariate model yielded one independent
baseline predictor for time to discontinuation, i.e.
duration of PD at start of LCIG (HR: 0.85; 95%
CI: 0.76–0.96; p = 0.009). The performed sensitivity
analysis, in which death was considered a reason for
discontinuation of treatment, confirmed the findings
of the univariable and multivariable Cox regression
analyses, i.e. duration of PD at baseline was the
only variable associated with time to discontinuation
([univariable analysis] HR: 0.83; 95% CI: 0.75–0.92;
p = 0.0004; [multivariable analysis with age as covari-
ate] HR 0.83; 95% CI 0.75–0.92; p = 0.0005; data not
shown).
Reasons for discontinuation and causes of death
In total, 18 patients (18.4%) discontinued LCIG
infusion and seven patients died during treatment
(7.1%). Based on the collected data, all patients died
for reasons unrelated to treatment, although the cause
of death was unknown in two patients (Table 3).
The other most common reasons for discontin-
uation were device-related side effects (n = 5; e.g.
recurrent tube dislocations) and efficacy being less
than expected by the patient (n = 5). Table 3 shows
all reasons for discontinuation.
Number of hospitalizations
During follow-up, 32 patients (32.7%) were hospi-
talized due to complications of LCIG treatment. This
group of patients needed 51 hospitalizations in total.
Most hospitalizations were related to problems with
Table 3
Reasons for discontinuation of LCIG infusion and causes of death
during treatment
Reason for discontinuation N = 18
Device-related side effects 5
Effect less than expected by patient 5
Switch to DBS 4
Effect less than expected by clinician 2
Switch to CAI 1
Drug-related side effects of LCIG 1
Cause of death N = 7
LCIG-related 0
Device-related 0
Other (not specified) 5
Unknown 2
Reasons for discontinuation and causes of death are expressed
as numbers. DBS, deep brain stimulation; CAI, continuous apo-
morphine infusion; LCIG, levodopa-carbidopa intestinal gel; PD,
Parkinson’s disease.
the PEG-J tube or T-port, such as dislocations, infec-
tions, or malfunctioning (Table 4). One patient was
hospitalized five times and stopped treatment after a
total duration of 3.3 years because of device-related
side-effects.
Overall, the incidence of LCIG-related hospi-
talizations was 0.20 per person per year. Patients
who discontinued LCIG infusion had a significantly
higher rate of hospitalizations compared to patients
continuing therapy (0.56 vs 0.13 hospitalizations per
person year; difference: 0.43; 95% CI of difference:
0.20–0.65; p < 0.0001). This difference remained sta-
tistically significant after excluding patients who
discontinued LCIG because of device-related side
effects (0.41 vs 0.13 hospitalizations per person year;
difference: 0.28; 95% CI of difference: 0.04–0.51;
p = 0.003).
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Table 4









Gastrointestinal perforation PEG-J 3
Occlusion PEG-J 3
Pain
After PEG-J placement 1




Inadvertently pulled-out PEG-J 1
Removal of T-port due to infection 1
Tilting T-port 1
Other, PEG-J-related 4
Other (N = 17)
Aggravation of dyskinesias needing re-titration 5






In our LCIG cohort we found a low rate of dis-
continuation with a median time to discontinuation
of 7.8 years. The results confirmed the heterogene-
ity in total duration of treatment, varying from a few
months to more than 9 years. At start of therapy, the
only patient characteristic predictive for time to dis-
continuation appeared to be duration of PD. Patients
who discontinued treatment had a higher incidence
rate of hospitalizations than patients who remained
on LCIG.
This study is the first overview of a cohort of Dutch
PD patients treated with LCIG. The results of this
study are similar to the findings of previous long-
term studies reporting annual rates of withdrawal of
7–13% and an average overall duration of treatment
of 7.6 years [10, 13, 14, 16, 30–32]. In addition, all
baseline characteristics of our cohort, the reported
reasons for discontinuation, and the considerably
high number of LCIG-related hospitalizations (i.e.,
serious adverse events) are comparable to the obser-
vations in other large patient groups [9, 10, 13, 15,
16, 20, 32].
In the present study, time to treatment discontin-
uation was chosen as the primary outcome to study
prognostic factors. We chose this outcome measure
because of its simplicity and its comprehensiveness.
Previously, it was argued that time to discontinua-
tion serves as a measure of effectiveness in illnesses
with a long-term course and need for long-term treat-
ment [12]. Time to discontinuation encompasses lack
of efficacy, intolerable side effects, dissatisfaction or
a combination of the aforementioned reasons [33].
Staying on treatment for a longer period of time
can be considered a success, as it may reflect ade-
quate symptom reduction, fewer hospitalizations and
a satisfactory quality of life [33]. Therefore, all dis-
continuations of LCIG display a lack of treatment
success. This also holds for switching to DBS or CAI
(n = 5), concerning patients not being satisfied with
LCIG.
We believe that studying time to treatment dis-
continuation using survival analysis has several
advantages. Firstly, survival analysis can effectively
cope with the uncertainty caused by censored obser-
vations [34]. Therefore, this statistical technique can
utilize the data of the whole cohort, in our case 98
patients, irrespective of whether a patient stopped
treatment or not. Using all data contributes to the
power of the statistical analyses. Secondly, time to
discontinuation can be studied easily and reliably in
retrospective cohorts, since discontinuation is an end-
point that will always be registered in medical charts.
Nevertheless, this method has difficulties to account
for competing risks, for example death, which might
lead to overestimation of the risk of discontinua-
tion. To overcome this problem, we chose to censor
deceased patients and perform a sensitivity analysis
in which we did the opposite [35].
The identified predictors of time to discontinuation
do only partly resonate with previous publications.
Firstly, the association between duration of PD at
baseline and time to discontinuation appears to
oppose the results of a Swedish cohort study [10].
While our findings imply that a longer duration of PD
is a predictor of a longer total duration of treatment,
patients discontinuing LCIG in Swedish cohort had a
significantly longer duration of PD at start of therapy.
This dissimilarity might be related to methodological
differences, since our association was based on a Cox
regression analysis while Nyholm et al. compared
the characteristics of patients who stopped treatment
with those who did not [10]. The latter did not take
into account variation in time-to-event data. Although
the observational design of the present study does
not allow for causal inferences, the listed reasons
for discontinuation (Table 3) do hint at possible
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explanations. One might speculate that patients with
shorter disease durations are more inclined to stop
with LCIG infusion because they have overly high
expectations of the treatment benefits. Another likely
explanation is that patients with shorter disease dura-
tions are more often still eligible for either DBS
or CAI, while LCIG frequently is the last available
option for patients who have had the diagnosis PD
for a longer period of time.
Another dissimilarity between our results and pre-
vious studies concerns the prognostic value of age at
start of treatment [15, 20, 23]. Our findings do not
provide evidence for the claim that elderly patients
are less suitable candidates for LCIG infusion [15].
In the present cohort, time to discontinuation of LCIG
was equally distributed across all age groups. Patients
aged ≥70 did not significantly differ from younger
patients, with the estimated hazard ratio of 0.74 being
in favor of older patients (no statistical significance).
Therefore, it might be concluded that advanced age
per se is not a contraindication for LCIG infusion.
The fact that this study has not been able to corrob-
orate previously establish baseline predictors, while
it did show possible new associations, may mean that
there are no robust baseline predictors for treatment
success. However, it seems unlikely that all patients
are equally suitable for LCIG. Possibly, factors dur-
ing treatment are of greater importance for treatment
effectiveness. This assumption is supported by the
higher rate of hospitalizations among patients from
our cohort who discontinued treatment. In this regard,
others have pointed out that a dedicated treatment
team is the cornerstone of successful long-term treat-
ment [20, 36].
The present study has several shortcomings.
Firstly, because of the retrospective design, some
patients might have been missed, which could have
created an incomplete cohort. Secondly, the explo-
ration of predictors was hampered by missing values,
especially for the variables disease severity and pres-
ences of cognitive impairment. Thirdly, our analysis
did not make a distinction between patients who
discontinued treatment permanently and patients for
whom the discontinuation was merely an intermis-
sion (n = 4). As a result, estimation of the total
duration of treatment is slightly lower than the real
cumulative time on LCIG. Fourthly, the number of
LCIG-related hospitalizations is probably lower than
the actual number of LCIG-related adverse events,
since we did not count the number of complications
that were handled at the outpatient clinic. Finally, we
did not study the detailed reasons why LCIG infu-
sion was chosen instead of an alternative advanced
therapy (DBS or CAI), nor did we report data on
clinical efficacy. Such data could have supported the
generalization of the study findings.
In conclusion, LCIG infusion is well-tolerated in
the long term. In our cohort, PD patients with a
shorter disease duration at baseline were more likely
to discontinue treatment earlier. In addition, elderly
patients appeared to be equally good candidates for
LCIG infusion. Future studies with larger patient
groups, preferably with a prospective design or a
meta-analysis, are needed to further improve our
understanding of baseline predictors of LCIG dis-
continuation. Eventually, this type of research will
help neurologists to decide which patient is a good
candidate for LCIG infusion.
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